Alpha 2.0
Login Register
» Authors » A S Veillard

A S Veillard

Explore the profile of A S Veillard including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 6
Citations 96
Followers 0
Related Specialties
Oncology
Endocrinology
Top 10 Co-Authors
S M Twigg
K H Williams
N Reed
A J Walsh
D F Lindsay
A Floquet
W Selby
F M Keane
R Rosell
L Elit
Published In
Ann Oncol
Diabetes Res Clin Pract
J Crohns Colitis
Diabet Med
Breast
Affiliations
Soon will be listed here.
Recent Articles
1.
Low alanine aminotransferase levels and higher number of cardiovascular events in people with Type 2 diabetes: analysis of the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study
Williams K, Sullivan D, Veillard A, OBrien R, George J, Jenkins A, et al.
Diabet Med . 2015 Oct; 33(3):356-64. PMID: 26433207
Aims: To determine whether alanine aminotransferase or gamma-glutamyltransferase levels, as markers of liver health and non-alcoholic fatty liver disease, might predict cardiovascular events in people with Type 2 diabetes. Methods:...
2.
Lower serum fibroblast activation protein shows promise in the exclusion of clinically significant liver fibrosis due to non-alcoholic fatty liver disease in diabetes and obesity
Williams K, Viera de Ribeiro A, Prakoso E, Veillard A, Shackel N, Bu Y, et al.
Diabetes Res Clin Pract . 2015 Apr; 108(3):466-72. PMID: 25836944
Unlabelled: Non-alcoholic fatty liver disease (NAFLD) is common in diabetes and obesity but few have clinically significant liver fibrosis. Improved risk-assessment is needed as the commonly used clinical-risk algorithm, the...
3.
Neoadjuvant chemotherapy with sequential anthracycline-docetaxel with gemcitabine for large operable or locally advanced breast cancer: ANZ 0502 (NeoGem)
McCarthy N, Boyle F, Zdenkowski N, Bull J, Leong E, Simpson A, et al.
Breast . 2014 Jan; 23(2):142-51. PMID: 24393617
Background: Neoadjuvant chemotherapy has a sound rationale for use in women with large operable breast cancer, and achievement of pathological complete response (pCR) is prognostic. Epirubicin and cyclophosphamide followed by...
4.
Implementing guidelines on the prevention of opportunistic infections in inflammatory bowel disease
Walsh A, Weltman M, Burger D, Vivekanandarajah S, Connor S, Howlett M, et al.
J Crohns Colitis . 2013 Apr; 7(10):e449-56. PMID: 23601754
Introduction: Opportunistic infections are a key safety concern in the management of patients with inflammatory bowel disease (IBD). Despite the existence of international guidelines, many gastroenterologists have not adopted routine...
5.
Cross-validation study of class III beta-tubulin as a predictive marker for benefit from adjuvant chemotherapy in resected non-small-cell lung cancer: analysis of four randomized trials
Reiman T, Lai R, Veillard A, Paris E, Soria J, Rosell R, et al.
Ann Oncol . 2011 Apr; 23(1):86-93. PMID: 21471564
Background: The IALT, JBR.10, ANITA and Cancer and Leukemia Group B 9633 trials compared adjuvant chemotherapy with observation for patients with resected non-small-cell lung cancer (R-NSCLC). Data from the metastatic...
6.
Ovarian cancer in elderly patients: carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in late relapse: a Gynecologic Cancer Intergroup (GCIG) CALYPSO sub-study
Kurtz J, Kaminsky M, Floquet A, Veillard A, Kimmig R, Dorum A, et al.
Ann Oncol . 2011 Mar; 22(11):2417-2423. PMID: 21402619
Background: CALYPSO (CAeLYx in Platinum Sensitive Ovarian) patients compared carboplatin-pegylated liposomal doxorubicin (C-PLD) with carboplatin-paclitaxel (C-P) in patients with late-relapsing recurrent ovarian cancer (ROC). We analyzed outcomes in patients ≥70...